Gilead dishes out $66M for San Diego biotech's 'tentacles' in cancer, inflammation
Gilead will pony up $66 million in an upfront payment and equity investment to collaborate with Tentarix Biotherapeutics on biologics for inflammatory diseases and oncology, the companies said Tuesday morning.
San Diego-based Tentarix could receive up to another $240 million if Gilead elects to acquire three of the biotech’s subsidiaries that house the oncology and inflammatory disease programs included in the pact, the partners said. That figure would be split evenly across the three programs, which use the startup’s so-called Tentacles platform.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
